Emily Mears
Family · Statesville, NCNPI 1225706344
Payments from drug & device makers
Across 134 payments — averaging $21.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$588
- Novo Nordisk$423
- Gilead$382
- Bayer$339
- AstraZeneca$279
- Lilly USA, LLC$205
- plus $685 from 14 others
What the payments were for
- Food & beverage$2,900100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 37 | $588 |
| Novo Nordisk | 16 | $423 |
| Gilead | 16 | $382 |
| Bayer | 24 | $339 |
| AstraZeneca | 4 | $279 |
| Lilly USA, LLC | 7 | $205 |
| Abbott | 3 | $106 |
| Viiv Healthcare Company | 3 | $81 |
| Axsome Therapeutics, Inc. | 1 | $78 |
| Daiichi Sankyo Inc. | 3 | $71 |
| GSK | 3 | $58 |
| Pfizer | 3 | $55 |
| Phathom Pharmaceuticals, Inc. | 3 | $39 |
| Organon | 2 | $38 |
| Exact Sciences | 2 | $37 |
| Astellas Pharma US Inc | 2 | $33 |
| Amgen | 2 | $30 |
| Viatris Specialty LLC | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Merck | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,900 in reported general payments places this provider in the 85th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 115 | $174,819 |
| JardianceEmpagliflozin | 53 | $67,844 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $37,404 |
| EliquisApixaban | 24 | $35,075 |
| MounjaroTirzepatide | 30 | $35,019 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 21 | $22,939 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $20,556 |
| JanuviaSitagliptin Phosphate | 18 | $18,668 |
| MyrbetriqMirabegron | 12 | $9,950 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $5,809 |
| Epinephrine | 12 | $4,530 |
| Novolog FlexpenInsulin Aspart | 15 | $4,214 |
| Gabapentin | 213 | $4,164 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $4,139 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $4,021 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $423 | $174,819115 claims |
| MerckJanumet Xr, Januvia | $17 | $41,60739 claims |
| PfizerEliquis | $55 | $35,07524 claims |
| Lilly USA, LLCMounjaro | $205 | $35,01930 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $58 | $24,69528 claims |
| Astellas Pharma US IncMyrbetriq | $33 | $9,95012 claims |
| AstraZenecaSymbicort | $279 | $5,80912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,522 family providers in North Carolina.
Other family in Statesville
- Kimberly WoodsStatesville$62K
- Deborah DaywaltStatesville$13K
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.